Osteopontin inhibits osteoblast responsiveness through the down-regulation of focal adhesion kinase mediated by the induction of low–molecular weight protein tyrosine phosphatase

Joji Kusuyama, Kenjiro Bandow, Tomokazu Ohnishi, Mitsuhiro Hisadome, Kaori Shima, Ichiro Semb, and Tetsuya Matsuguchi

*Department of Oral Biochemistry, Field of Developmental Medicine, ‡Department of Dermatology, Field of Advanced Therapeutics, and ‡Department of Oral Pathology, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan; ‡Department of Oral Biology and Tissue Engineering, Meikai University School of Dentistry, Sakato 350-0283, Japan

ABSTRACT Osteopontin (OPN) is an osteogenic marker protein. Osteoblast functions are affected by inflammatory cytokines and pathological conditions. OPN is highly expressed in bone lesions such as those in rheumatoid arthritis. However, local regulatory effects of OPN on osteoblasts remain ambiguous. Here we examined how OPN influences osteoblast responses to mechanical stress and growth factors. Expression of NO synthase 1 (Nos1) and Nos2 was increased by low-intensity pulsed ultrasound (LIPUS) in MC3T3-E1 cells and primary osteoblasts. The increase of Nos1/2 expression was abrogated by both exogenous OPN overexpression and recombinant OPN treatment, whereas it was promoted by OPN-specific siRNA and OPN antibody. Moreover, LIPUS-induced phosphorylation of focal adhesion kinase (FAK), a crucial regulator of mechanoresponses, was down-regulated by OPN treatments. OPN also attenuated hepatocyte growth factor–induced vitamin D receptor (Vdr) expression and platelet-derived growth factor–induced cell mobility through the repression of FAK activity. Of note, the expression of low–molecular weight protein tyrosine phosphatase (LMW-PTP), a FAK phosphatase, was increased in both OPN-treated and differentiated osteoblasts. CD44 was a specific OPN receptor for LWW-PTP induction. Consistently, the suppressive influence of OPN on osteoblast responsiveness was abrogated by LMW-PTP knockdown. Taken together, these results reveal novel functions of OPN in osteoblast physiology.

INTRODUCTION Osteoblasts, which are derived from mesenchymal stem cells, have multiple roles in bone metabolism by producing various types of polypeptidic factors. Bone matrix proteins such as osteopontin (OPN), bone sialoprotein (BSP), and osteocalcin (OCN) are produced by mature osteoblasts in the process of bone formation and tissue mineralization (Staines et al., 2012; Neve et al., 2013). Osteoblasts also synthesize receptor activator of nuclear factor κ-B ligand (RANKL) and osteoprotegerin for the regulation of osteoclastic activities in bone resorption (Walsh and Choi, 2014). We have also showed that osteoblasts stably express several chemokines for guiding the migration and activation of immune cells (Bandow et al., 2007; Maeda et al., 2015).
OPN is a 33-kDa glycoprotein belonging to small integrin-binding ligand N-linked glycoprotein (SIBLING) family and is recognized as a major marker of osteogenic differentiation (Kruger et al., 2014). Increased expression of OPN is found in the lesions of bone metastasis (Carlinfante et al., 1991; Faccio et al., 1998) and T-lymphocytes (Xu et al., 2005; Chen et al., 2010). Physiological functions of osteoblasts are influenced by a wide range of exogenous factors, such as growth factors, inflammatory cytokines, bacterial infections, oxygen concentration, and mechanical stress (Neve et al., 2011). The consequent dysfunctions of osteoblasts frequently lead to pathological processes of bone metabolic diseases through uncontrolled bone remodeling. On the other hand, reports have shown that osteoblast or osteocyte-derived SIBLING family proteins, including BSP and dentin matrix protein 1 (DMP1), modulate osteoblast functions through their receptor signaling primary osteoblasts. OPN treatment did not affect other osteogenic marker gene expressions, including alkaline phosphatase (Alp), bone sialoprotein (Bsp), and osteocalcin (Ocn), in undifferentiated MC3T3-E1 cells (Figure 1C). Pretreatment by recombinant OPN had suppressive effects on Nos1 and Nos2 inductions by LIPUS (Figure 1, D and E). In addition, we examined the effects of LIPUS on OPN expression in MC3T3-E1 cells and primary osteoblasts. LIPUS stimulation promoted Opn mRNA expression only in primary osteoblasts (Figure 1F).

Conversely, we examined OPN effects on the mechanoresponsiveness of osteoblasts with the inhibition of endogenous OPN protein. MC3T3-E1 cells were cultured in osteogenic differentiation medium for sufficient secretion of OPN from osteoblasts. The OPN-specific small interfering RNA (siRNA) was transfected on day 10 to decrease OPN production (Figure 2A). The OPN knockdown significantly promoted LIPUS-induced Nos1 and Nos2 expression (Figure 2B). Moreover, treatment by neutralizing anti-OPN antibody efficiently increased the basal level of Nos1 and LIPUS-induced levels of Nos1 and Nos2 in both MC3T3-E1 cells (Figure 2C) and primary osteoblasts (Figure 2D). These results suggest that OPN negatively regulates LIPUS-induced expression of Nos1 and Nos2 in osteoblasts.

FIGURE 1: OPN attenuates the effects of LIPUS on osteoblasts. (A) MC3T3-E1 Tet-on cells, stably transfected with pTRE2Hyg-OPN, were incubated in regular medium with or without 2 μg/ml DOXY for 48 h or in osteogenic differentiation medium for 10 d. Cell lysates were analyzed for OPN protein expression by Western blotting. Significant difference from the control by Student’s t test (*p < 0.01). (B) Three independent MC3T3-E1 cell clones with inducible expression of OPN were incubated with or without 2 μg/ml DOXY for 48 h and either unstimulated or stimulated with LIPUS for 20 min. After additional incubation for 2 h, total RNA was isolated and reverse transcribed. The gene expressions of Nos1 and Nos2 were analyzed by real-time PCR. The same experiments were performed at least three times, with consistent results. Relative mRNA expression levels in comparison with ribosomal protein L 13a (Rpl13a) are shown. Error bars represent SD. Significant difference from the control by Student’s t test (*p < 0.01) (C–E) MC3T3-E1 cells (C, D) and mouse primary osteoblasts (E) were treated with 100 ng/ml recombinant OPN protein for 6 h (C), followed by LIPUS stimulation (D, E) and analysis as in B. (F) MC3T3-E1 cells and mouse primary osteoblasts were stimulated by LIPUS for 20 min, followed by incubation for 6 h and analysis as in B.

RESULTS
OPN suppresses the effects of mechanical stimulation on osteoblasts
To examine the functional effects of OPN on mechanical responses in osteoblasts, we prepared MC3T3-E1 cells, which inducibly overexpress OPN on doxycycline (DOXY) stimulation, using the Tet-on inducible expression system. The expression levels of OPN protein in DOXY-treated cells were very similar to those observed in differentiated osteoblasts (Figure 1A). Low-intensity pulsed ultrasound (LIPUS) is a mechanical stress that has been used as a clinical application to promote bone fracture healing (Padilla et al., 2014). Therapeutic potency of LIPUS is partly explained by nitric oxide (NO) production from osteoblasts, which orchestrates the balance of bone remodeling action between osteoblasts and osteoclasts (Reher et al., 2002; Wang et al., 2004). We found that LIPUS-induced NO synthase 1 (Nos1) and Nos2 mRNA expression is significantly inhibited by OPN overproduction (Figure 1B). We then examined the effects of recombinant OPN on LIPUS stimulation of MC3T3-E1 cells and primary osteoblasts.

ONL in osteoblast physiology
In this study, we explore how OPN affects responses of osteoblasts to exogenous stimulants, including mechanical stress and cytokines. OPN inhibits osteoblast responsiveness via dephosphorylation of focal adhesion kinase (FAK) mediated by the increased expression of low–molecular weight protein tyrosine kinase (LMW-PTP).
OPN attenuates LIPUS-induced FAK phosphorylation

FAK is a cytoplasmic protein tyrosine kinase that has been reported to play an important role in the mechanical stress signaling pathway of osteoblastic cell lines and primary cultured osteoblasts (Pommerenke et al., 2002; Boutahar et al., 2004; Young et al., 2009; Wang et al., 2011). FAK activation also has been reported in MC3T3-E1 cells treated with ultrasound stimulation (Wang et al., 2004). We confirmed significant LIPUS-induced phosphorylation of FAK (Y576/577) in the vector control MC3T3-E1 cells (Figure 3A). Of note, LIPUS-induced FAK phosphorylation was significantly inhibited by the induction of OPN overexpression (Figure 3A). Consequently, treatment with recombinant OPN also attenuated LIPUS-induced FAK phosphorylation in MC3T3-E1 cells (Figure 3B).

Conversely, transient knockdown of OPN expression in differentiated MC3T3-E1 cells increased the phosphorylated level of FAK after LIPUS treatment (Figure 3C). We then pretreated MC3T3-E1 cells with dasatinib, a specific Src inhibitor that reduces Y576/577 FAK phosphorylation, and found that it significantly decreased LIPUS-induced Nos1, Nos2, and c-fos mRNA expression (Figure 3D). These results raised the possibility that OPN might inhibit LIPUS-induced gene expression of Nos1 and Nos2 through the down-regulation of FAK activity.

OPN inhibits osteoblast responses to hepatocyte growth factor and platelet-derived growth factor through the repression of FAK activity

Because OPN efficiently repressed FAK activation by LIPUS, we next examined whether OPN influences osteoblast responses to other types of stimuli. Because previous studies reported that hepatocyte growth factor (HGF; Tsai et al., 2012) and platelet-derived growth factor (PDGF; Ren et al., 2012) induced FAK phosphorylation in osteoblast cell lines, we analyzed the effects of OPN on HGF- and PDGF-induced FAK phosphorylation in osteoblasts. FAK was rapidly phosphorylated at Y576/577 by HGF and PDGF proteins, and the phosphorylation levels were significantly inhibited by the induction of OPN expression (Figure 4, A and B). Similarly, treatment with recombinant OPN protein suppressed the effects of HGF and PDGF on FAK phosphorylation (Figure 4, C and D). Although HGF and PDGF treatments did not induce Nos1 or Nos2 expression (unpublished data), a previous report that HGF facilitated the differentiation of human bone marrow–derived stem cells into the osteoblastic phenotype by the up-regulation of vitamin D receptor (VDR) expression (Chen et al., 2012) prompted us to analyze the effects of OPN on Vdr expression in immature osteoblasts stimulated with HGF. We found that HGF significantly elevated the mRNA level of Vdr in MC3T3-E1 cells, which was suppressed by DOXY-induced overexpression of OPN (Figure 4E). Consistent with this result, treatment with recombinant OPN also attenuated the Vdr gene expression induced by HGF (Figure 4F).

We subsequently measured suppressive effects of OPN on PDGF in a cell-spreadling assay. PDGF has been reported to stimulate cell spreading and migration of osteoblasts through FAK-induced G-protein–coupled receptor kinase–interacting protein 1 (GIT-1) activation (Ren et al., 2012). MC3T3-E1 cells were pretreated with PDGF for 30 min and seeded on fibronectin-coated dishes to quantify cell areas at 60 min. PDGF stimulation significantly increased the eosin-stained cytoplasmic area of osteoblasts, which was abrogated by OPN treatment (Figure 4G). These results were consistent with the reduced FAK phosphorylation in the presence of OPN protein.
Conversely, functional OPN inhibition by OPN-specific siRNA or anti-OPN neutralizing antibody significantly up-regulated HGF and PDGF-induced FAK phosphorylation (Figure 4, H and I). It also up-regulated HGF-induced Vdr expressions in mature osteoblasts (Figure 4, J and K). Taken together, these data indicate that OPN suppresses cellular responses of osteoblasts not only to mechanical stress but also to cytokines such as HGF and PDGF via inhibition of FAK activity.

**OPN inactivates FAK through the induction of LMW-PTP**

FAK activity is down-regulated by various tyrosine phosphatases, including LMW-PTP, src homology region 2 domain–containing phosphatase-2 (SHP-2), and protein tyrosine phosphatase containing proline-glutamine-serine-threonine–rich motifs (PTP-PEST). LMW-PTP is a ubiquitously expressed 18-kDa tyrosine-specific phosphatase (Raugei et al., 2002), which dephosphorylates FAK in fibroblasts (Rigacci et al., 2002) and T-cells (Giannoni et al., 2003). We found that Lmw-pto mRNA expression was highly induced by treatment with OPN recombinant protein in MC3T3-E1 cells (Figure 5A) and primary osteoblasts (Figure 5B). We also analyzed the OPN dose response of Lmw-pto mRNA expression in MC3T3-E1 cells (Figure 5C). On the other hand, HGF and PDGF, both of which are activators of FAK, did not induce Lmw-pto mRNA expression (Figure 5, A and B). Shp-2 and Pt-p-pest expressions were not affected by the OPN treatments (Figure 5D). DOXY-induced overexpression of OPN also increased Lmw-pto mRNA expression (Figure 5E). We also confirmed that the protein level of LMW-PTP was significantly increased by treatment with recombinant OPN protein in osteoblasts (Figure 5F). OPN also induced Lmw-pto mRNA expression in fibroblasts, including mouse embryonic fibroblasts (MEFs) and NIH-3T3 cells (Figure 5G).

We next cultured MC3T3-E1 cells in the induction medium of osteogenesis and analyzed Lmw-pto expression during osteogenic differentiation. The gene expression of Lmw-pto was gradually elevated from day 15 of differentiation (Figure 5H). Of interest, the time course of Lmw-pto mRNA induction was similar to that of Opn (Figure 5H). These results raised the possibility that OPN might down-regulate FAK activity by dephosphorylation via induction of LMW-PTP expression in osteoblasts.

To examine how the increased expression of LMW-PTP affects osteoblast responses to mechanical stress and cytokines, we established MC3T3-E1 Tet-on Flag-tagged LMW-PTP cells. In this inducible cell line, LIPUS-induced FAK phosphorylation was strongly inhibited in the presence of DOXY (Figure 6A). Similarly to LIPUS stimulation, HGF- and PDGF-induced FAK phosphorylation was significantly suppressed by LMW-PTP overexpression (Figure 6, B and C). Furthermore, LIPUS-induced Nos1/Nos2 expression and HGF-induced Vdr expression were significantly attenuated by induced expression of LMW-PTP (Figure 6, D and E).

We then prepared siRNA against LMW-PTP to explore its involvement in OPN-induced suppression of FAK activation. Transient transfection with LMW-PTP siRNA efficiently inhibited LMW-PTP protein expression in MC3T3-E1 cells (Figure 6F). At 24 h after siRNA transfection, we treated cells with recombinant OPN, followed by 6 h incubation and LIPUS stimulation. We found that LIPUS-induced FAK phosphorylation was enhanced, whereas the inhibitory effect of OPN on FAK phosphorylation was negated by the LIPUS-PTP knockdown (Figure 6G). LMW-PTP siRNA transfection similarly abrogated the suppressive effect of OPN on HGF-induced FAK phosphorylation (Figure 6H). We also found that LIPUS-induced Nos1 mRNA levels were further increased by LMP-PTP knockdown in MC3T3-E1 cells (Figure 6I) and primary osteoblasts (Figure 6J). Of note, the suppressive influence of OPN on the LIPUS-induced Nos1 expression was abrogated by LMP-PTP knockdown (Figure 6, I and J). These results indicated that LMW-PTP is an OPN-inducible
phosphatase that down-regulates the FAK-induced cellular responses in osteoblasts.

**CD44 is a specific OPN receptor for LMW-PTP induction**

OPN interacts with a variety of cell surface receptors, including several integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1) and CD44 (Kazanecki et al., 2007; Wang and Denhardt, 2008). Histologically, OPN and its receptors, αv- and β-integrin subunits (Lim et al., 2005), and CD44 (Zoller, 2011) are coexpressed in osteoblasts. To determine which OPN receptor is functionally involved in LMW-PTP induction in osteoblasts, we used cyclic RGD peptide, which blocks the binding of OPN at αv integrin, as well as neutralizing antibodies against CD29 (integrin α5β1) and CD44. We found that the blockade of CD44 specifically suppressed OPN-induced Lmw-ptp mRNA and protein expression, whereas the two other blockers had no significant effects on LWM-PTP (Figure 7, A and B). We also confirmed the binding of OPN to CD44 by immunoprecipitation (Figure 7C). This result suggests that OPN-induced LMW-PTP expression is especially mediated through CD44.

**OPN suppresses the effects of mechanical stimulation on human mesenchymal stem cells**

Finally, we examined the suppressive effects of OPN on the response to mechanical stress in UE6E7-16, a human mesenchymal stem cell line. Pretreatment by recombinant human OPN had suppressive effects on FAK phosphorylation by LIPUS (Figure 8A). Consistently, OPN treatment increased LMW-PTP expression in UE6E7-16 cells. Next UE6E7-16 cells were differentiated into osteoblastic cells in osteogenic differentiation medium to induce OPN secretion. After differentiation for 10 d, UE6E7-16 cells highly expressed Opn and Lmw-ptp mRNAs (Figure 8B). Treatment of the differentiated UE6E7-16 cells by neutralizing anti-OPN antibody efficiently increased the both basal and LIPUS-induced levels of Nost (Figure 8C). These results suggest that a negative regulatory effect of OPN is observed in human mesenchymal stem cells as in mouse counterparts.

**DISCUSSION**

OPN, also called secreted phosphoprotein 1 (SPP1), was initially identified as an extracellular matrix protein that had inhibitory effects on the formation and growth of hydroxyapatite crystals in bone matrix and other organs (Sodek et al., 2000). Osteoblasts are the major source of OPN in bone tissue. Although the expression of OPN is generally recognized as a middle-stage marker of osteogenic differentiation (Kruger et al., 2014), skeletal analysis of Opn-knockout mice showed that OPN is not essential for normal mouse development and osteogenesis (Rittling et al., 1998). Of note, however, a more detailed study using Fourier-transformed infrared microspectroscopy and infrared imaging indicated that bone mineral content and size were significantly increased in Opn-knockout mice (Boskey et al., 2002), indicating an essential regulatory role of OPN in bone metabolism. The precise roles of OPN in osteoblastic functions remain ambiguous. Our present findings indicate that OPN has suppressive
Our findings show that OPN negatively regulates the osteoblast responses to these two cytokines. Furthermore, we demonstrated that OPN also negatively regulates osteoblast responses to a mechanical stress by LIPUS, which is an efficient promoter of osteogenic differentiation (Kusuyama et al., 2014), raising the possibility that OPN might be considered as a general inhibitory cytokine of osteoblastic functions.

In this regard, note that OPN is also recognized as an inflammatory cytokine (Wang and Denhardt, 2008). OPN is produced by various types of immune cells, including lymphocytes, macrophages, NK cells, and dendritic cells. Several studies reported that OPN expression is increased in the bone tissues of chronic bone inflammatory diseases such as rheumatoid arthritis (Ohshima et al., 2002), periodontitis (Kido et al., 2001), and metastatic cancer in bone (Carlinfante et al., 2003), suggesting the possibility that immune cell-derived OPN might exert negative effects on osteoblastic functions in the inflamed bone tissue.

FAK, also referred to as protein tyrosine kinase 2 (PTK2), is widely involved in the attachment and sensitivity of cells to the extracellular matrix organization (Bellido, 2010). Interaction between integrin and extracellular structure induces FAK autophosphorylation and activation, which in turn activates Src and ERK signaling pathways. FAK also plays an important role in the cellular responses to mechanical stress (Thompson et al., 2012). Although osteoblast-specific FAK-knockout mice exhibited normal skeletal phenotype and osteogenic differentiation, bone fracture healing was delayed and disrupted (Kim et al., 2007), suggesting that FAK might be essentially in maintaining the integrity of bone tissues. Indeed, our present data confirm that FAK becomes phosphorylated by various exogenous stimuli, including mechanical stress, HGF, and PDGF (Figures 3A and 4, A and B). Furthermore, a specific FAK inactivation significantly inhibited LIPUS-induced mRNA expression of Nos1, Nos2, and c-fos (Figure 3D), indicating that FAK is an essential signal mediator of LIPUS.

Of note, our present data indicate that the inhibitory effects of OPN on osteoblast functions are specifically mediated by the inactivation of FAK signaling (Figures 3 and 4). FAK is dephosphorylated by various protein tyrosine phosphatases, such as SHP-2 (Lee et al., 2015), PTP-PEST (Lyons et al., 2001), and LMW-PTP (Rigacci et al., 2002). We showed that endogenous and exogenous OPN stimulation significantly increased gene and protein expression of LMW-PTP (Figure 5). On the other hand, Shp-2 and Ptp-pest mRNA expression was not affected by OPN treatment (Figure 5C). FAK inactivation by LMW-PTP has been reported to impair fibroblast

**FIGURE 5:** Stimulation with OPN increased the expression of LMW-PTP in osteoblasts. (A–D) MC3T3-E1 cells (A, C, D) and primary osteoblasts (B) were stimulated with HGF, OPN, or PDGF for 1 or 3 h. Gene expression was analyzed by real-time RT-PCR. The same experiments were performed at least three times with consistent results. Relative mRNA expression levels in comparison with Rpl13a are shown. Error bars represent SD. Significant difference from the control by Student’s t test (\(* p < 0.01\)). (E) MC3T3-E1 and MC3T3-E1 Tet-on OPN cell lines were incubated with or without 2 μg/ml DOXY for 24 or 48 h. The gene expression of Lmw-ptp was analyzed as in A. (F) MC3T3-E1 cells and primary osteoblasts were stimulated by OPN for 6 h. LMW-PTP protein expression was analyzed by Western blotting. Significant difference from the control by Student’s t test (\(* p < 0.01\)). (G) MEFs and NIH-3T3 cells were stimulated with OPN for 1 or 3 h. The same analysis was performed as in D. (H) MC3T3-E1 cells were induced to differentiate by the addition of ascorbic acid and β-glycerophosphate for the indicated days. Gene expression of Lmw-ptp and Opn during osteogenic differentiation was examined by real-time RT-PCR.
migration (Rigacci et al., 2002) and T-cell adhesion (Giannoni et al., 2003). To our knowledge, the present study is the first report showing the relationship between OPN and LMW-PTP in a broad range of osteoblast functions. Of interest, Lmw-ptp expression was gradually increased and correlated well with Opn expression during osteogenic differentiation (Figure 5, D and E), indicating a possible regulatory involvement of LMW-PTP in the process of osteoblast differentiation. A previous study reported that Src is inactivated by increased expression and activity of LMW-PTP during osteoblast differentiation (Zambuzzi et al., 2008). The Src-FAK signaling pathway might be regulated by OPN-induced LMW-PTP expression in differentiated osteoblasts.

OPN treatment also increased Lmw-ptp mRNA in fibroblasts similarly to in osteoblasts (Figure 5G), demonstrating that this OPN effect is not limited to osteoblasts. Several studies showed that the elevated OPN expression affects physiological functions of fibroblasts. For example, increased OPN expression modified adhesive properties and integrin-mediated signal transduction in NIH-3T3 cells (Chambers et al., 1992). Paracrine signaling by tumor-derived OPN reprogrammed normal fibroblasts into tumor-promoting inflammatory fibroblasts (Sharon et al., 2015). Given that FAK signaling complexes are known to play an integral role in fibroblastic functions such as cell proliferation, collagen synthesis, and wound healing (Rustad et al., 2013), OPN-induced LMW-PTP expression might regulate FAK-associated molecular events in fibroblasts.

We found that PDGF-induced FAK phosphorylation (Figure 6C) and cell spreading (unpublished data) were significantly impaired by LMW-PTP overexpression, indicating that LMW-PTP might negatively regulate PDGF-induced physiological functions of osteoblasts through the dephosphorylation of FAK. However, a previous study indicated that LMW-PTP dephosphorylates PDGF receptor and reduces the growth rate of fibroblasts in response to PDGF stimulation (Chiarugi et al., 1998). Therefore it is possible that LMW-PTP inhibits osteoblast responses to PDGF via direct dephosphorylation of PDGF receptor rather than FAK.

Expression of LMW-PTP was reported in myogenic and neurogenic differentiation of C2C12 myoblasts and PC12 phenochromocytoma cells, respectively (Fiaschi et al., 2001). Cell differentiation up-regulated the expression and enzymatic activity of LMW-PTP in each cell line (Fiaschi et al., 2001). Consistent with this previous report, we found that LMW-PTP...
Finally, our present findings might provide insight into the clinical effectiveness of LIPUS for bone diseases. We showed that both endogenous overexpression and exogenous addition of OPN significantly suppressed LIPUS-induced expression of Nos1 and Nos2, which are regulatory synthases for NO production (Figure 1). Because the therapeutic effect of LIPUS has partly been explained by ultrasound-induced NO synthesis by osteoblasts (Reher et al., 2002), our results suggest that osteoblast responses to mechanical stress such as LIPUS might vary, depending on the local tissue concentration of OPN. This might explain why LIPUS treatment has variable clinical effects on bone fracture healing.
MATERIALS AND METHODS
Reagents and antibodies
Recombinant mouse and human OPN was purchased from Peprotech (Rocky Hill, NJ). Recombinant mouse HGF was provided by Mitsubishi Tanabe Pharma (Osaka, Japan). Recombinant mouse PDGF-AA was purchased from Prospeck (Rehovot, Israel). Datasinib, a specific FAK Y576/577 inhibitor, was purchased from Focus Biomolecules (Plymouth Meeting, PA). Cyclo-ωβ3-integrin binding cyclic RGD peptide was from Anaspec (Fremont, CA). Anti-mouse CD29 neutralizing antibody was from Biolegend (San Diego, CA). Anti-mouse CD44 neutralizing antibody was from BD Biosciences (San Jose, CA). Antibodies recognizing total and phosphorylated (Y575/576) forms of FAK were obtained from Cell Signaling Technology (Danvers, MA). Antibodies against OPN and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA). M2 anti-Flag antibody was from Sigma-Aldrich (St. Louis, MO). The antibody against LMW-PTP was purchased from R&D systems (Minneapolis, MN).

Cell culture
MC3T3-E1, a mouse osteoblastic cell line, was obtained from RIKEN Cell Bank (Tsukuba, Japan) and maintained in Eagle's α-MEM (WAKO) containing 10% fetal bovine serum (FBS), 50 μg/ml penicillin, and 50 mg/ml streptomycin. NIH-3T3, a mouse fibroblastic cell line, was obtained from RIKEN Cell Bank and maintained in D-MEM (WAKO) containing 10% FBS, 50 μg/ml penicillin, and 50 mg/ml streptomycin. UE6E7-16, a human mesenchymal stem cell line, was obtained from RIKEN Cell Bank and maintained in PowerDex by10 medium (Glycotech, Yokohama, Japan). Primary osteoblasts were isolated from newborn mouse calvariae. Briefly, calvariae were excised under aseptic condition, rinsed twice with ice-cold phosphate-buffered saline (PBS), and incubated in enzyme solution (PBS containing 0.25% collagenase I and 0.125% trypsin) with agitation. After consecutive enzyme treatment (6 × 20 min), the fourth, fifth, and sixth supernatants were centrifuged. The pellets were resuspended in α-MEM for cell culture. MEFs were prepared from 14-d postcoital C57BL/6 mouse embryos as previously described (Coats et al., 1999). Osteogenic differentiation of MC3T3-E1, primary osteoblasts, and UE6E7-16 was induced by the addition of 280 μM ascorbic acid 2-phosphate trisodium and 5 mM β-glycerophosphate in the culture medium.

Tet-on inducible expression system
The establishment of the MC3T3-E1 pEF1α-Tet-on cell line has been described (Matsuguchi et al., 2009). The coding cDNAs for mouse OPN and LMW-PTP were amplified by reverse transcription PCR (RT-PCR) with specific primers using total RNA from C57BL/6 mouse primary osteoblasts as the template. After the confirmation of the DNA sequences, these cDNAs were cloned into pEFBOS-Flag (Matsuguchi et al., 2001) vector, producing pEFBOS-Flag-mOPN and pEFBOS-Flag-mLMW-PTP, respectively. The cDNA inserts of these plasmids were recloned into pTRE2-Hyg vector (Clontech Laboratories), producing inducible expression plasmids pTRE2-Hyg-OPN and pTRE2-Hyg-Flag-LMW-PTP, respectively. pTRE2-Hyg-Flag-OPN and pTRE2-Hyg-Flag-LMW-PTP were stably transfected into the MC3T3-E1 pEF1α-Tet-on cell line by HilyMax (Dojindo, Kumamoto, Japan). After selection with 0.15 mg/ml hygromycin B, the isolated resistant clones were tested for inducible protein expression from the inserted cDNAs with 2 μg/ml DOXY. Three individual cell lines with good inducible protein expression were analyzed for each construct.

Ultrasound application
Cells were stimulated using a LIPUS-generating system (Teijin Pharma, Tokyo, Japan) as previously described (Kusuyama et al., 2014). The LIPUS signal consisted of a series of 1.5-MHz, 200-μs burst sine waves at 1.0 kHz and was delivered at 30 mW/cm². The pattern and intensity of the LIPUS signal were essentially the same as used in clinical practice and animal model experiments.

RNA interference
Chemically synthesized siRNA duplexes specific for murine LMW-PTP: r(CCAUUGAGCGUCACUCAGdTdT and Ur(GAGUGAGCUGCUAUGG)dTdT were purchased from Sigma-Aldrich. OPN-specific and nontargeting control siRNA duplexes (Control siRNA-A) were from Santa Cruz Biotechnology. The duplex siRNAs were transfected using HilyMax according to manufacturer's instructions.

| Gene symbol | Primer (5′–3′) |
|-------------|----------------|
| mNos1 | TATGTGGCAGAAGCTCCAGA |
| mNos2 | ATGGAGCATCCTCAATTCAGCA |
| mc-fos | GGAATACCGCTGTGATCAAATGG |
| mVdr | CGTGCAAGACGTAAGTACAGG |
| mLmw-tp | GCCGATAAGGCAAGACAGATTA |
| mShp-2 | GTGAGGAGAGGGAAGGACAA |
| mPtp-pest | CCGACCTAGAGAGTTCGAGC |
| hRpl13a | AGGTCGAGCTCGTGTTG |
| hNos1 | CCAACACCCTAAACCTAGTCG |
| hOpn | CATCACCTGTCGCATAACAG |
| hLmw-tp | GCCCGCGCAATACCAAA |

TABLE 1: Primers used in this study.
Protein cross-linking and immunoprecipitation
MC3T3-E1 cells were stimulated by 100 ng/ml OPN for 1 h. Cells were further incubated in PBS with 50 mM bis(sulfosuccinimidyl) suberate (BSA), an amine-to-amine cross-linker, for 20 min at room temperature. The cell lysates were prepared in PLC lysis buffer and incubated with OPN antibody for 2 h at 4°C, followed by incubation with protein A–Sepharose beads (GE Healthcare Biosciences, Piscataway, NJ) for an additional 1 h. The beads were washed three times in ice-cold PLC lysis buffer, suspended in SDS sample buffer, and heated at 95°C for 10 min. The eluted proteins were applied to SDS–PAGE and analyzed by Western blotting.

Cell-spreading assays
Cells were incubated with normal medium for 12 h and serum-starved medium for 6 h and then suspended in normal medium. Cells were seeded on fibronectin-coated dishes with or without PDGF and OPN treatment and fixed with 10% formaldehyde at 60 min. Cells were stained to visualize the cytoplasm by eosin solution. Ten attached cells were randomly selected for measurement of cell-spreading area using ImageJ software. Statistical analysis was performed using Student’s t test.

ACKNOWLEDGMENTS
We thank Yoko Amita and Yuka Kajiya for secretarial assistance. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Kanazawa Medical Research Foundation, the Nakatomi Foundation, the Japan Foundation for Aging and Health, and Teijin Pharma, which supplied the LiPUS device.

REFERENCES
Bandow K, Maeda A, Kakimoto K, Kusuyama J, Shamoto M, Ohnishi T, Matsuguchi T (2010). Molecular mechanisms of the inhibitory effect of lipopolysaccharide (LPS) on osteoblast differentiation. Biochem Biophys Res Commun 402, 755–761.

Bandow K, Nishikawa Y, Ohnishi T, Kakimoto K, Soejima K, Iwabuchi S, Kuroe K, Matsuguchi T (2007). Low-intensity pulsed ultrasound (LiPUS) induces RANKL, MCP-1, and MIP-1beta expression in osteoblasts through the angiotensin II type 1 receptor. J Cell Physiol 211, 392–398.

Bellido T (2010). Antagonistic interplay between mechanical forces and glucocorticoids in bone: a tale of kinases. J Cell Biol 111, 1–6.

Berti A, Rigacci S, Raugei G, Degl’Innocenti D, Ramponi G (1994). Inhibition of cellular response to platelet-derived growth factor by low Mr phosphotyrosine protein phosphatase overexpression. FEBS Lett 349, 7–12.

Boskey AL, Spevak L, Paschalis E, Doty SB, McGee MD (2002). Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 71, 145–154.

Boutahar N, Guignandon A, Vico L, Lafage-Proust MH (2004). Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation. J Biol Chem 279, 30588–30599.

Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinig D, Andersson G (2003). Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20, 437–444.

Chambers AF, Behrendt EL, Wilson SM, Denhardt DT (1992). Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, -ras-transformed NIH 3T3 cells. Anticancer Res 12, 43–47.

Chen G, Zhang X, Li R, Fang L, Niu X, Zheng Y, He D, Xu R, Zhang JZ (2010). Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum 62, 2900–2908.

Chen K, Aenlle KK, Curtis KM, Roos BA, Howard GA (2012). Hepatocyte growth factor (HGF) and 1,25-dihydroxyvitamin D together stimulate human bone marrow-derived stem cells toward the osteogenic phenotype by HGF-induced up-regulation of VDR. Bone 51, 69–77.

Chiarugi P, Ciri P, Marra F, Raugei G, Fiaschi T, Camici G, Manao G, Romanelli RG, Ramponi G (1998). The Src and signal transducers and activators of transcription pathways as specific targets for low molecular weight phosphotyrosine-protein phosphatase in platelet-derived growth factor signaling. J Biol Chem 273, 6776–6785.

Coats S, Whyte P, Fero ML, Lacy S, Chung G, Randeil E, Firpo E, Roberts JM (1999). A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells. Curr Biol 9, 163–173.

Facco R, Grano M, Colucci S, Zallone AZ, Quaranta V, Pelletier AJ (1998). Activation of alphavbeta3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin. Biochem Biophys Res Commun 249, 522–525.

Fiaschi T, Chiarugi P, Buricchi F, Giannoni E, Taddei ML, Talini D, Cozzi G, Zecchi-Orlandini S, Raugei G, Ramponi G (2001). Low molecular weight protein-tyrosine phosphatase is involved in growth inhibition during cell differentiation. J Biol Chem 276, 4916–49163.

Giannone E, Chiarugi P, Cozzi G, Magnelli L, Taddei ML, Fiaschi T, Buricchi F, Raugei G, Ramponi G (2003). Lympocyte function-associated antigen-1-mediated cell adhesion is impaired by low molecular weight phosphotyrosine phosphatase-dependent inhibition of FAK activity. J Biol Chem 278, 36763–36776.

Hou X, Wu X, Huang P, Zhan J, Zhou T, Ma Y, Qin T, Luo R, Feng Y, Xu Y, et al. (2015). Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma. Int J Cancer 137, 1672–1678.

Iwadate H, Kobayashi H, Kanno T, Asano T, Saito R, Sato S, Suzuki E, Watanabe H, Ohira H (2014). Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. Int J Rheum Dis 17, 50–56.

Kosarad A, Fisher LW (2006). Bone sialoprotein enhances migration of bone marrow stromal cells through matrices by bridging MMP-2 to alaph(3beta1) integrin. J Bone Miner Res 21, 1627–1636.

Kazekowski C, Utzick D, DT (2007). Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102, 912–924.

Kido J, Nakamura T, Asahara Y, Sawa T, Kohn K, Nagata T (2001). Osteopontin in gingival crevicular fluid. J Periodontal Res 36, 328–333.

Kim JB, Leucht P, Luppen CA, Park YJ, Begg HS, Damsky CH, Helms JA (2007). Reconciling the roles of FAK in osteoblast differentiation, osteoclast remodeling, and bone regeneration. Bone 41, 39–51.

Kruger TE, Miller AH, Godwin AK, Wang J (2014). Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol 89, 330–341.

Kusuyama J, Bandow K, Shamoto M, Kakimoto K, Ohnishi T, Matsuguchi T (2014). Low intensity pulsed ultrasound (LiPUS) influences the multilinear differentiation of mesenchymal stem and progenitor cell lines through ROCK-Cot/Tp2z-MEK-ERK signaling pathway. J Biol Chem 289, 10330–10344.

Lee KJ, Yoo YH, Kim MS, Yadav BK, Kim Y, Lim D, Hwangbo C, Moon KW, Kim D, Jeoung D, et al. (2015). CD99 inhibits CD98-mediated beta1 integrin signaling through SHP2-mediated FAK dephosphorylation. Exp Cell Res 336, 211–222.

Lim JY, Taylor AF, Li Z, Vonder HA, Donahue HU (2005). Integrin expression and osteopontin regulation in human fetal osteoblastic cells mediated by substratum surface characteristics. Tissue Eng 11, 19–29.

Lyons PD, Dunty JM, Schaefer EM, Schaller MD (2001). Inhibition of the catalytic activity of cell adhesion kinase beta by protein-tyrosine phosphatase-PEST-mediated dephosphorylation. J Biol Chem 276, 24422–24431.

Maeda A, Bandow K, Kusuyama J, Kakimoto K, Ohnishi T, Miyawaki S, Matsuguchi T (2015). Induction of CXCCL2 and CCL2 by pressure force requires IL-1beta-MyD88 axis in osteoblasts. Bone 74, 76–82.
Martin A, Liu S, David V, Li H, Karydis A, Feng Q, Quarles LD (2011). Bone proteins PHEX and DMP1 regulate fibroblastic growth factor FgI23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 25, 2551–2562.

Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, Ohnishi T (2009). JNK activity is essential for Aft4 expression and late-stage osteoblast differentiation. J Bone Miner Res 24, 398–410.

Matsuguchi T, Muskakharoent, Johnson TR, Kraft AS, Yoshiike Y (2001). A novel mitogen-activated protein kinase phosphatase is an important negative regulator of lipopolysaccharide-mediated c-Jun N-terminal kinase activation in mouse macrophage cell lines. Mol Cell Biol 21, 6999–7009.

Miao H, Burnett E, Kinch M, Simon E, Wang B (2000). Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2, 62–69.

Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, Zambonin-Zallone A, Ross FP, Teitelbaum SL, Cheresi S, et al. (1991). Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 266, 20369–20374.

Neve A, Corrado A, Cantatore FP (2011). Osteoblast physiology in normal and pathological conditions. Cell Tissue Res 343, 289–302.

Neve A, Corrado A, Cantatore FP (2013). Osteocalcin: skeletal and extraneous effects. J Cell Physiol 228, 1149–1153.

Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Waktani S, et al. (2002). Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 29, 2061–2067.

Padilla F, Puts R, Vico L, Raum K (2014). Stimulation of bone repair with ultrasound: a review of the possible mechanistic effects. Ultrasound 54, 1125–1145.

Pommerenke H, Schmidt C, Durr F, Nebe B, Luthen F, Muller P, Rychly J, et al. (1991). Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 266, 20369–20374.

Rustad KC, Wong VW, Gurtner GC (2013). The role of focal adhesion complexes in fibroblast mechanotransduction during scar formation. Differentiation 86, 87–91.

Sharon Y, Raz Y, Cohen N, Ben-Shmuel A, Schwartz H, Geiger T, Erez N (2015). Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res 75, 963–973.

Sodek J, Ganss B, McKeel MD (2000). Osteopontin. Crit Rev Oral Biol Med 11, 279–303.

Staines KA, MacRae VE, Farquharson C (2012). The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214, 241–255.

Thompson WR, Rubin CT, Rubin J (2012). Mechanical regulation of signaling pathways in bone. Gene 503, 179–193.

Tsai SY, Huang YL, Yang WH, Tang CH (2012). Hepatocyte growth factor-induced BMP-2 expression is mediated by c-Met receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts. Int Immunopharmacol 13, 156–162.

Walsh MC, Choi Y (2014). Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol 5, 511.

Wang B, Du T, Wang Y, Yang C, Zhang S, Cao X (2011). Focal adhesion kinase signaling pathway is involved in mechanotransduction in MG-63 cells. Biochem Biophys Res Commun 410, 671–676.

Wang FS, Kuo YR, Wang CJ, Yang KD, Chang PR, Huang YT, Huang HC, Sun YC, Yang YJ, Chen YJ (2004). Nitric oxide mediates ultrasound-induced hypoxia-inducible factor-alpha activation and vascular endothelial growth factor-A expression in human osteoblasts. Bone 35, 114–123.

Wang KX, Dinhardt DT (2008). Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19, 333–345.

Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G, Ni L, Xu R, Hong J, Zhang JZ (2005). Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 115, 1060–1067.

Young SR, Gerard-O’Riley R, Kim JB, Pavalko FM (2009). Focal adhesion kinase is important for fluid shear stress-induced mechanotransduction in osteoblasts. J Bone Miner Res 24, 411–424.

Zambuzzi WF, Granjeiro JM, Parikh K, Yuvaraj S, Peppelenbosch MP, Ferreira CV (2008). Modulation of Src activity by low molecular weight protein tyrosine phosphatase E2Z production by human osteoblasts. Bone 41, 236–241.

Ren Y, Yu L, Fan J, Rui Z, Hua Z, Zhang Z, Zhang N, Yin G (2012). Phosphorylation of GIT1 tyrosine 321 is required for association with FAK at focal adhesions and for PDGF-activated migration of osteoblasts. Mol Cell Biochem 365, 109–118.

Rigacci S, Rovida E, Dello Sbarba P, Berti A (2002). Low Mr phosphotyrosine protein phosphatase associates and dephosphorylates p125 focal adhesion kinase, interfering with cell motility and spreading. J Biol Chem 277, 41631–41636.

Ritting SR, Matsumoto HN, McKeel MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998). Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13, 1101–1111.